GLUCAGON KIT
Country: Canada
Language: English
Source: Health Canada
Summary of Product characteristics
(SPC)
10-07-2012
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
GLUCAGON (RECOMBINANT DNA ORIGIN)
Available from:
ELI LILLY CANADA INC
ATC code:
H04AA01
INN (International Name):
GLUCAGON
Dosage:
1MG
Pharmaceutical form:
KIT
Composition:
GLUCAGON (RECOMBINANT DNA ORIGIN) 1MG
Administration route:
INTRAMUSCULAR
Units in package:
1 ML
Prescription type:
Schedule D
Therapeutic area:
GLYCOGENOLYTIC AGENTS
Product summary:
Active ingredient group (AIG) number: 0142861001; AHFS:
Authorization status:
CANCELLED POST MARKET
Authorization date:
2023-12-18
Summary of Product characteristics
GLUCACON (rDNA Origin) Product Monograph
Page 1 of 32
PRODUCT MONOGRAPH
GLUCAGON
GLUCAGON FOR INJECTION, RDNA ORIGIN
1 MG GLUCAGON PER VIAL
Sterile Lyophilized Powder and Diluent
Hyperglycemic Agent
©
Eli Lilly Canada Inc.
3650 Danforth Avenue
Toronto, Ontario
M1N 2E8
1-888-545-5972
Date of Approval:
July 9, 2012
www.lilly.ca
Submission Control No: 139332
GLUCACON (rDNA Origin) Product Monograph
Page 2 of 32
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
..............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS
.........................................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
6
DRUG INTERACTION
............................................................................................................
8
DOSAGE AND ADMINISTRATION
.....................................................................................
9
OVERDOSAGE
......................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
.................................................................. 12
STORAGE AND STABILITY
...............................................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................... 13
PART II: SCIENTIFIC INFORMATION
..............................................................................
14
PHARMACEUTICAL INFORMATION
...............................................................................
14
CLINICAL TRIALS
...........................................................................................................
Read the complete document
